www.dailypolitical.com ·
Atricure Nasdaqatrc Issues Quarterly Earnings Results
Topic context
This topic has been covered 376470 times in the last 30 days across our monitored publishers.
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedAtriCure, a medical device company focused on cardiac surgery and pain management, reported earnings that beat estimates. Revenue growth is driven by product momentum in pain management, though minimally invasive sales face challenges. The company's margin remains negative, but EBITDA improvement signals operational leverage. No direct commodity or supply chain scarcity is indicated.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- AtriCure reported Q1 2026 EPS of $0.00, beating consensus of ($0.07).
- Revenue of $141.25M exceeded $139.75M estimate, up 14.3% YoY.
- Adjusted EBITDA nearly doubled to $17.1M.
- Net margin remains negative at -0.83%.
- FY 2026 EPS guidance raised to 0.000-0.040.
Related stories
fool.com
Keysight Keys Q2 2026 Earnings Transcript
livemint.com
Haryana Bars Petrol Diesel Cabs for Aggregators What Means Pm Modis Austerity Push Ncrs Aqi Fuel News
proactiveinvestors.com.au
The Morning Catch Up Asx Set to Open Lower Ahead of Pivotal Nvidia Earnings
nbclosangeles.com
Spacex Confirms Plans for IPO
manilatimes.net